MD Anderson begins brachytherapy seed trial for prostate cancer
MD Anderson Cancer Center in Houston has initiated orders of Cesium-131 brachytherapy seeds from IsoRay, as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer, which is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatment.
The current phase of the study will compare Cesium-131 to other, previously used isotopes, according to the Richland, Wash.-based company. Principal investigator Steven J. Frank, MD, is seeking to evaluate Cesium-131 in its capability to address intermediate risk prostate cancer and its quality of life benefits.
The study also will also evaluate prostate-specific antigen (PSA) response and the patient's return to urinary function baseline as well as normal lifestyle activities.
The current phase of the study will compare Cesium-131 to other, previously used isotopes, according to the Richland, Wash.-based company. Principal investigator Steven J. Frank, MD, is seeking to evaluate Cesium-131 in its capability to address intermediate risk prostate cancer and its quality of life benefits.
The study also will also evaluate prostate-specific antigen (PSA) response and the patient's return to urinary function baseline as well as normal lifestyle activities.